London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Who would sell at 13.5 ? Maybe they bought circa 11.5 last week but why sell now not when it was higher? I honestly can't work out their strategy?
it doesn't pre-suppose that. Instead that they are routine/general tests of which I take 20% as high risk. Right forst time. My mistake
that the 3.5 Mill currently done by Labs are high risk cases. Otherwise seems it could be a ball-park figure for roll-out as it states 'developed world' and we know we are excluding USA, so I am calling that Europe??.
At roll out we are targeting iro 700,000 tests if all 600 labs came on-board? (20% of 3.5 Mill ) "Initially the new tests will be primarily offered to the 20 per cent. of women at high risk of an affected fetus in the developed world with subsequent expansion to lower risk pregnancies and wider geographies........ It is estimated that there are currently 600 laboratories performing around 3.5 million Down's Syndrome screens annually in Europe."
inkisblue, why do you feel the authorities would baulk at the price? Amniocentesis (existing invasive needle procedure): Min £800 depending on trust Competitors: £400 - £450 for specialist lab abroad Prematiha: £300 - £350 Price is competitive and has a quicker turn around. Sorry you've based your sale decision on incorrect info.
Vanvagabond, This is a spot on explanation. They are targeting about 600 UK labs with this model.
I'm hearing people say "they" will walk if down to near 11. Whose " they" and why? If it goes nearer 11 who would take up their options..? No incentive then.
Selling and buying back might be tempting ... but look at that spread!
Amounts are too small. Unless there are bigger sells in the back ground. Madness to sell now, unless they are hoping to but back at a lower price.
post consolidation by the new year, that's the board's immediate price target as we all know and we will get there I believe quite easily.
Like many others, I'm weighing up whether to put more money in by way of the excess allotment. I'm a bit surprised as to why the SP hasn't moved down towards 0.11 or the equivalent of 11p after consolidation which itself is quite a discount from the closing price before suspension. My experience of consolidations is that they usually mean an overall drop in value. Any expert opinions would be appreciated.
I have received this message from Hargreaves Lansdown today Hargreaves Lansdown will inform you of your options regarding the Vialogy Open Offer shortly. If you wish to take up your entitlements in the Offer you can do so by calling us on 0117 9809912 or sending a Secure Message. The terms of the Offer allow qualifying holders to purchase 1 post-consolidation share for every 400 existing ordinary shares held at the end of business on 12 June 2014, at a cost of 11p. In addition holders can apply for additional new shares on top of their basic entitlement. The consolidation will take place on 4 July on the basis of 1 new ordinary share in place of every 100 shares held at the end of business on 3 July 2014.
Small sells ....?
It was just a glitch at Barclays on their system. Sorry all.
We are suspended???!!!
Why?
We are not looking to DISPLACE the competition, that's the beauty of it, we are looking to stream line their current process so that's it not just specialised labs that can do it thus increasing our target market. Premaitha’s non-invasive pre-natal IONA® Test is based on next generation DNA sequencing technology. To date the complexity of this technology has meant that tests which employ next generation sequencing technology are only available in a small number of specialised reference laboratories. The IONA® Test is designed to simplify and standardise the next generation sequencing workflow so that laboratory customers without a background in molecular technology can offer the new tests. Rather than compete with the current providers to displace them, Premaitha supplies a product to these laboratories allowing them to continue to provide their services.
Pre takes a blood sample eg from mum's arm for diagnostics not the big needle thru the belly so no infection repercussions for the baby or risk of miscarriage . Looks pricey in comparison with the two main competitors in UK but less risky. Should be acceptable to authorities on clinical grounds though they might baulk at price. Would be good to know if they have a pipeline of products beyond this, they hint at further developments in their bumf . Took my profits and out for the moment will continue to monitor. Gla Dyor
Forgot to add that I will speak to you next week after I have digested all 155 pages !!
Evening mate Thanks for some very informative postings this evening. vanvaga Good link, thanks
Thanks for posting that link to the RNS. I've saved it to read in full tomorrow. I note the date of the RNS is 12 June. I was away on holiday when it came out. I have again checked the VIY website and cannot find it there; surely it should be on the website by now.